Recently, a team led by Professor Li Wanwan, a researcher at the School of Materials Science and Engineering and the Zhangjiang Advanced Research Institute of Shanghai Jiao Tong University, has successfully developed a multi-index in vitro detection system for quantum dot liquid biochips.
Liquid biochip technology is a novel detection technique suitable for nucleic acids and protein biomarkers. It boasts high throughput, sensitivity, and the ability to simultaneously analyze dozens of targets in a single tube sample, significantly enhancing detection efficiency. The core of this technology lies in special fluorescent polymer microspheres and corresponding signal analysis. However, due to its high technological barriers and manufacturing difficulties, it has long been monopolized by foreign countries, posing a typical bottleneck issue in the field of in vitro diagnostics.
After 18 years of efforts, the team led by Li Wanwan has achieved a breakthrough in the complete chain of technology, from quantum dot fluorescent microspheres to detection analyzers and supporting assay reagents. They have successfully established a quantum dot liquid biochip technology platform with independent intellectual property rights.
The team led by Li Wanwan at Shanghai Jiao Tong University has pioneered a novel approach in the international arena by proposing a membrane emulsification method for the preparation of quantum dot fluorescent encoding microspheres, considering the monopolization and blockade of encoding microsphere technology abroad. Following a breakthrough in the preparation of core encoding microspheres, the team, in collaboration with enterprises, successfully developed the world's only fully automatic liquid biological chip system utilizing single-laser technology. This system boasts advantages such as small size, full automation, high throughput, low sample volume, high accuracy, good repeatability, wide linear range, and low cost. Moreover, based on this detection system, a series of multi-index detection reagents for proteins/nucleic acids related to cancer, autoimmune diseases, cardiovascular diseases, and infectious diseases have been developed. Currently, a series of detection instruments and supporting reagent kits have obtained CE certification from the European Union and 15 registration certificates from the China National Medical Products Administration (NMPA). Additionally, numerous series of joint detection reagents are either under application or in the approval process. This capability has enabled the team to compete with foreign counterparts in high-end technological equipment, and the promotion of this technology has been implemented globally, breaking the monopoly of international corporations.
